Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 7, 2026, 2:54 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 3,614 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Scottsdale, Arizona Clear all
Active, not recruiting Phase 2 Interventional

A Study to Learn About the Safety of BIIB080 Injections and Whether They Can Improve Symptoms of Participants With Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild AD Dementia Between 50 to 80 Years of Age

NCT05399888
View directory record Official record
Conditions
Mild Cognitive Impairment Due to Alzheimer's Disease, Alzheimer's Disease Dementia
Interventions
BIIB080, BIIB080-matching placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
50 Years to 80 Years
Enrollment
416 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
36
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Sun City, Arizona + 30 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Jun 7, 2026, 2:54 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Lenalidomide and Low-Dose Dexamethasone in Patients With Previously Treated Multiple Myeloma and Kidney Dysfunction

NCT00790842
View directory record Official record
Conditions
Multiple Myeloma, Plasma Cell Neoplasm
Interventions
Lenalidomide, Dexamethasone, Anticoagulants
Drug
Lead sponsor
PrECOG, LLC.
Other
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2018
U.S. locations
16
States / cities
Scottsdale, Arizona • Atlanta, Georgia • Chicago, Illinois + 13 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2018 · Synced Jun 7, 2026, 2:54 AM EDT
Terminated No phase listed Observational

Relationship Between Alterations in the GI Microbiome and GI Inflammation on Symptom Burden in Women With Breast Cancer Receiving Chemotherapy

NCT06238986
View directory record Official record
Conditions
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8
Interventions
Non-Interventional Study
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
20 Years and older · Female only
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
2
States / cities
Scottsdale, Arizona • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 24, 2025 · Synced Jun 7, 2026, 2:54 AM EDT
Completed Phase 4 Interventional

TAXUS ARRIVE 2: A Multi-Center Safety Surveillance Program

NCT00569751
View directory record Official record
Conditions
Cardiovascular Disease, de Novo Coronary Lesions
Interventions
TAXUS™ Express2™ Paclitaxel-Eluting Coronary Stent System
Device
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years and older
Enrollment
5,016 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
53
States / cities
Scottsdale, Arizona • Bakersfield, California • Rancho Mirage, California + 49 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2008 · Synced Jun 7, 2026, 2:54 AM EDT
Completed Phase 4 Interventional Results available

A Study Evaluating the Efficacy and Impact on Health-related Quality of Life of Levocetirizine in Adults With Seasonal Allergic Rhinitis

NCT00621959
View directory record Official record
Conditions
Seasonal Allergic Rhinitis
Interventions
levocetirizine dihydrochloride, placebo
Drug
Lead sponsor
UCB Pharma
Industry
Eligibility
18 Years to 65 Years
Enrollment
596 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
26
States / cities
Scottsdale, Arizona • Hot Springs, Arkansas • Little Rock, Arkansas + 23 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2020 · Synced Jun 7, 2026, 2:54 AM EDT
Completed Phase 1 Interventional

A Multiple-dose Study of ASP8374, an Immune Checkpoint Inhibitor, as a Single Agent and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors

NCT03260322
View directory record Official record
Conditions
Advanced Solid Tumors
Interventions
ASP8374, Pembrolizumab
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years and older
Enrollment
169 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
19
States / cities
Scottsdale, Arizona • Los Angeles, California • Sacramento, California + 14 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2025 · Synced Jun 7, 2026, 2:54 AM EDT
Completed Phase 2 Interventional

Study to Assess the Efficacy of Larazotide Acetate for the Treatment of Celiac Disease

NCT00492960
View directory record Official record
Conditions
Celiac Disease
Interventions
larazotide acetate, placebo, 900 mg gluten
Drug · Dietary Supplement
Lead sponsor
9 Meters Biopharma, Inc.
Industry
Eligibility
18 Years to 72 Years
Enrollment
171 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
17
States / cities
Scottsdale, Arizona • Colorado Springs, Colorado • Chicago, Illinois + 14 more
Source: ClinicalTrials.gov public record
Updated Sep 19, 2017 · Synced Jun 7, 2026, 2:54 AM EDT
Completed Phase 3 Interventional

Thymosin Plus PEG-Interferon in Non-Cirrhotic Hepatitis C Patients Who Did Not Respond to Interferon or Interferon Plus Ribavirin

NCT00040027
View directory record Official record
Conditions
Hepatitis C, Hepatitis C, Chronic
Interventions
thymalfasin (thymosin alpha 1) + PEGinterferon alfa-2a, placebo + PEGinterferon alfa-2a
Drug
Lead sponsor
SciClone Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
46
States / cities
Mobile, Alabama • Scottsdale, Arizona • Berkeley, California + 36 more
Source: ClinicalTrials.gov public record
Updated Jan 14, 2008 · Synced Jun 7, 2026, 2:54 AM EDT
Completed Phase 1 Interventional

A Study of Intratumoral IMO-2125 in Patients With Refractory Solid Tumors

NCT03052205
View directory record Official record
Conditions
Refractory Solid Tumors, Melanoma
Interventions
IMO-2125
Drug
Lead sponsor
Idera Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
8
States / cities
Scottsdale, Arizona • Tucson, Arizona • San Francisco, California + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2020 · Synced Jun 7, 2026, 2:54 AM EDT
Recruiting Not applicable Interventional

Sirolimus Coated BALloon Versus Standard Balloon Angioplasty in The Treatment of Below The Knee Arterial Disease

NCT06182397
View directory record Official record
Conditions
Arterial Disease of Legs, Below-the-knee Obstruction, PAD - Peripheral Arterial Disease
Interventions
MagicTouch PTA Sirolimus drug coated balloon, Placebo balloon angioplasty
Device
Lead sponsor
Concept Medical Inc.
Industry
Eligibility
21 Years and older
Enrollment
368 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
29
States / cities
Scottsdale, Arizona • Los Angeles, California • Clearwater, Florida + 22 more
Source: ClinicalTrials.gov public record
Updated Jan 1, 2026 · Synced Jun 7, 2026, 2:54 AM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study of Nab-Paclitaxel and Gemcitabine With or Without Olaratumab (LY3012207) in Participants With Metastatic Pancreatic Cancer

NCT03086369
View directory record Official record
Conditions
Metastatic Pancreatic Cancer
Interventions
Olaratumab, Nab-paclitaxel, Gemcitabine, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
184 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
32
States / cities
Scottsdale, Arizona • Tucson, Arizona • Fayetteville, Arkansas + 26 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2022 · Synced Jun 7, 2026, 2:54 AM EDT
Completed Phase 2 Interventional

Imiquimod in Preventing Cervical Cancer in Women With Cervical Neoplasia

NCT00031759
View directory record Official record
Conditions
Cervical Cancer, Precancerous Condition
Interventions
imiquimod, Ablative or excisional therapy
Drug · Procedure
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older · Female only
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2010
U.S. locations
8
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Honolulu, Hawaii + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2016 · Synced Jun 7, 2026, 2:54 AM EDT
Completed Phase 3 Interventional Results available

Quetiapine Fumarate (SEROQUEL) in the Treatment of Adolescent Patients With Schizophrenia and Bipolar I Disorder

NCT00227305
View directory record Official record
Conditions
Schizophrenia, Bipolar I Disorder
Interventions
quetiapine fumarate
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
10 Years to 17 Years
Enrollment
381 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
31
States / cities
Dothan, Alabama • Scottsdale, Arizona • Cerritos, California + 28 more
Source: ClinicalTrials.gov public record
Updated Jan 7, 2013 · Synced Jun 7, 2026, 2:54 AM EDT
Completed Phase 1 Interventional

A Study of ZL-1211 in Patients With Advanced Solid Tumor

NCT05065710
View directory record Official record
Conditions
Advanced Solid Tumor
Interventions
ZL-1211
Drug
Lead sponsor
Zai Biopharmaceutical (Suzhou) Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
10
States / cities
Scottsdale, Arizona • Lynwood, California • Indianapolis, Indiana + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2024 · Synced Jun 7, 2026, 2:54 AM EDT
Completed Phase 3 Interventional Results available

Safety and Effectiveness of AZLI (an Inhaled Antibiotic) in Adults With Non-Cystic Fibrosis Bronchiectasis

NCT01313624
View directory record Official record
Conditions
Bronchiectasis
Interventions
AZLI, Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
266 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
36
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Los Angeles, California + 29 more
Source: ClinicalTrials.gov public record
Updated Apr 15, 2014 · Synced Jun 7, 2026, 2:54 AM EDT
Completed No phase listed Observational

Combined CXL//UV and PRK or LASIK in Forme Fruste Keratoconus or Eyes With Potential Risk of Ectasia

NCT01726283
View directory record Official record
Conditions
Fruste Keratoconus, Risk of Ectasia
Interventions
Corneal Cross-Linking, Riboflavin
Device · Drug
Lead sponsor
Cxlusa
Industry
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
8
States / cities
Scottsdale, Arizona • San Diego, California • Miami, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 23, 2015 · Synced Jun 7, 2026, 2:54 AM EDT
Completed Phase 3 Interventional Results available

A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Moderately to Severely Active Crohn's Disease Who Failed Prior Biologic Treatment

NCT03104413
View directory record Official record
Conditions
Crohn's Disease
Interventions
placebo for risankizumab IV, risankizumab SC, risankizumab IV
Drug
Lead sponsor
AbbVie
Industry
Eligibility
16 Years to 80 Years
Enrollment
618 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
114
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Tempe, Arizona + 89 more
Source: ClinicalTrials.gov public record
Updated Jun 13, 2022 · Synced Jun 7, 2026, 2:54 AM EDT
Completed Phase 2 Interventional Results available

Study of Ruxolitinib (INCB018424) Sustained Release Formulation in Myelofibrosis Patients

NCT01340651
View directory record Official record
Conditions
Myelofibrosis
Interventions
Ruxolitinib
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
3
States / cities
Scottsdale, Arizona • Winter Park, Florida • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 9, 2014 · Synced Jun 7, 2026, 2:54 AM EDT
Completed Phase 3 Interventional

FACTS I: A Study to Test the Safety and Effectiveness of a New Medication on the Treatment of Active Ulcerative Colitis

NCT00064441
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
OPC-6535 Tablets (drug)
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
375 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
23
States / cities
Scottsdale, Arizona • Los Angeles, California • Santa Ana, California + 18 more
Source: ClinicalTrials.gov public record
Updated May 9, 2012 · Synced Jun 7, 2026, 2:54 AM EDT
Completed Phase 1 Interventional

A Dose Escalation Study of SF1126, a PI3 Kinase (PI3K) Inhibitor, Given By Intravenous (IV) Infusion in Patients With Solid Tumors

NCT00907205
View directory record Official record
Conditions
Advanced or Metastatic Solid Tumors, Cancer, Solid Cancers
Interventions
SF1126
Drug
Lead sponsor
Semafore Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
4
States / cities
Scottsdale, Arizona • Tucson, Arizona • Atlanta, Georgia + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 12, 2013 · Synced Jun 7, 2026, 2:54 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Clinical Efficacy and Safety of Subcutaneously Administered C1-esterase Inhibitor in the Prevention of Hereditary Angioedema

NCT01912456
View directory record Official record
Conditions
Hereditary Angioedema Types I and II
Interventions
Low-volume C1-esterase inhibitor, Higher-volume C1-esterase inhibitor, Low-volume placebo, Higher-volume placebo
Biological
Lead sponsor
CSL Behring
Industry
Eligibility
12 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
19
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Bell Gardens, California + 16 more
Source: ClinicalTrials.gov public record
Updated Jan 28, 2021 · Synced Jun 7, 2026, 2:54 AM EDT
Completed Phase 1 Interventional

A Safety And Pharmacokinetic Study With CVX-045 In Patients With Advanced Solid Tumors

NCT00879554
View directory record Official record
Conditions
Advanced Solid Tumors, Neoplasms, Carcinoma, Cancer, Malignancy
Interventions
CVX-045
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
3
States / cities
Scottsdale, Arizona • Santa Monica, California • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 12, 2010 · Synced Jun 7, 2026, 2:54 AM EDT
Completed Phase 2 Interventional

Erlotinib and Temozolomide With Radiation Therapy in Treating Patients With Glioblastoma Multiforme or Other Brain Tumors

NCT00039494
View directory record Official record
Conditions
Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma
Interventions
erlotinib hydrochloride, 3-dimensional conformal radiation therapy, temozolomide
Drug · Radiation
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
171 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
139
States / cities
Mobile, Alabama • Scottsdale, Arizona • Jacksonville, Florida + 82 more
Source: ClinicalTrials.gov public record
Updated Aug 1, 2013 · Synced Jun 7, 2026, 2:54 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

A Safety and Preliminary Efficacy Study of CC-99282, Alone and in Combination With Anti-lymphoma Agents in Participants With Relapsed or Refractory Non-Hodgkin Lymphomas (R/R NHL)

NCT03930953
View directory record Official record
Conditions
Lymphoma, Non-Hodgkin
Interventions
CC-99282, Rituximab, Obinutuzumab, Tafasitamab, Valemetostat
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
438 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
8
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Tampa, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 18, 2026 · Synced Jun 7, 2026, 2:54 AM EDT